March 6, 2019 / 9:38 PM / 7 months ago

Allergan's add-on treatment for depression fails late-stage studies

March 6 (Reuters) - Allergan Plc said on Wednesday its experimental add-on treatment for major depressive disorder failed to meet the main goals of three late-stage studies.

The trials evaluated the efficacy, safety and tolerability of Allergan’s treatment, rapastinel, compared to a placebo, both in combination with antidepressant therapy (ADT) in patients with depression who had a partial response to ADT, the company said. (Reporting by Manogna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below